Advanced search
Publication Cover
Journal of Medical Economics Volume 23, 2020 - Issue 5
Submit an article Journal homepage
4,027
Views
8
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study

Sebastian StintzingMedical Department, Division of Hematology, Oncology, and Tumor Immunology (CCM), Charité Universitätsmedizin, Berlin, Germany;
,
Ilse van OostrumIngress Health, Rotterdam, the Netherlands;
,
Chris P. PescottMerck KGaA, Darmstadt, Germany; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-7763-9326
ORCID Icon,
Philippe RongaMerck KGaA, Darmstadt, Germany;
,
Bart HeegIngress Health, Rotterdam, the Netherlands; ORCID Iconhttp://orcid.org/0000-0002-9226-3232
ORCID Icon &
Volker HeinemannDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany
Pages 448-455 | Received 20 Sep 2019, Accepted 24 Dec 2019, Published online: 17 Jan 2020

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.